structure in first source
Also Known As:
Networked: 13 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results


1. Youdim, Moussa B H: 8 articles (08/2012 - 04/2002)
2. Amit, Tamar: 6 articles (08/2012 - 05/2003)
3. Bar-Am, Orit: 6 articles (08/2012 - 05/2003)
4. Weinreb, Orly: 3 articles (08/2012 - 01/2010)
5. Yogev-Falach, Merav: 3 articles (06/2004 - 05/2003)
6. Weinstock, Marta: 2 articles (05/2003 - 04/2002)
7. Kupershmidt, Lana: 1 article (08/2012)
8. Mandel, Silvia: 1 article (01/2010)
9. Dashtipour, Khashayar: 1 article (09/2007)
10. Chen, Jack J: 1 article (09/2007)

Related Diseases

1. Parkinson Disease (Parkinson's Disease)
2. Dementia (Dementias)
3. Basal Ganglia Diseases (Basal Ganglia Disease)
4. Alzheimer Disease (Alzheimer's Disease)
04/30/2002 - "We have therefore developed a number of novel drugs based on rasagiline (N-propargyl-1R-(+)-aminoindan), a potent anti-Parkinson-propargyl-containing MAO-B inhibitor drug with structural resemblance to selegiline, for the treatment of Alzheimer's disease. "
05/01/2003 - "Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326 and TV3279 [(N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate], respectively were derived from rasagiline, for the treatment of Alzheimer's disease (AD). "
12/01/2001 - "Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S)Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022. "
01/01/2010 - "This indication and recent therapeutic approaches, entailing new drug candidates possessing diverse pharmacological properties and acting on multiple targets, have stimulated the development of two multifunctional chimeric propargylamine-derivatives: 1) ladostigil (TV3326, [(N-propargyl-(3R) 1-(R)-aminoindan-5yl)-ethyl methyl carbamate)], which combines the pharmacophore of rasagiline, with the carbamate moiety of the cholinesterase inhibitor rivastigmine, as a potential treatment for Alzheimer's disease and Lewy body disease; and 2) M30 5-[(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline], where the propargylamine moiety of rasagiline was embedded onto the backbone of the neuroprotective and brain permeable iron chelator 8-hydroxyquinoline-derivative, VK28 as a potential treatment for various neurodegenerative disorders. "
5. Neurodegenerative Diseases (Neurodegenerative Disease)

Related Drugs and Biologics

1. Monoamine Oxidase (MAO)
2. rasagiline (Azilect)
3. (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate
4. methyl carbamate
5. Carbon Monoxide
6. Acetylcholine (Acetylcholine Chloride)
7. Cholinesterases (Cholinesterase)
8. (N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate
9. Oxyquinoline (8 Hydroxyquinoline)
10. Iron